My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
02/07/2023
CBCC
>
Meetings
>
2020's
>
2023
>
02/07/2023
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
3/21/2023 2:37:00 PM
Creation date
3/21/2023 1:58:03 PM
Metadata
Fields
Template:
Meetings
Meeting Type
BCC Regular Meeting
Document Type
Agenda Packet
Meeting Date
02/07/2023
Meeting Body
Board of County Commissioners
Jump to thumbnail
< previous set
next set >
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
232
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
.. .. ...... <br />"measis,a paper claim submitted by a;Memlw for Cctyeroli,-Drugs dispense(fwe <br />'UWtMW etssh" means the actual inglreaTient cost and Aspewing fee amount paid by t" t i t <br />1 tem when the Claim is adjudicated 6tt the ft.ficipeft Pharmatc#s as sm . in to Veaft. . <br />Participating Pharmacy remittances related to t Mat's *dins. <br />"PDL" means tltE P$ Pa%rmance bft List, ghi+e:h 4s u liBtd pharmaceutical products, created <br />and maintained by PBM, as amended from tittle to time, which--#,o ba been approved by PBM's pharmacy <br />and therapeutics committee; attd ( 000 w10 v* h=pharmaceutarOAl.p6p ticts <br />should be given favorable considetadlot► bit Ob*their parUca <br />articip"g Prharnmcv" rnvatts. any i ar Vbarnmcy with whicbM w aa'tpag Mebo s til fates <br />has executed an agreement to pilot £b ,-to Members but lace fpclude any mail order or <br />specialty pharmacy affiliated with any such 'l�ticipating Pharmacy: Pa"Wpating Pharmacies are <br />independent contractors .a '=. <br />"means the self-funded prescrip* M dft b06WW#) administered and/or sponsored by ctieftt. <br />*"Pl. en Adm'mt "stratoe' means the Plan sponsor or committee designated by the Plan sponsor with respect to <br />the Plan, as contemplated by Section 3 (16)(A) of ERISA. <br />1,TJW Desien" means drug coverage, days' supply linii eflotx, C69 $hare; irormulay(fa ludilfg Pormuh ry <br />C <br />divg,sattection and relative cost indication) and other PrescriptionV"OProgram specifications applicable to <br />j <br />thaftecription Drug Program designated for Client as set forth.;' 06r Agreement orotherwise documented <br />between the Parties. <br />"PMPM" mom per Member per month fee, if applicable, as determined by Administrator from tliR: <br />EIigibility Flies. <br />I <br />"Prescription Dru Claim" means a Member Submitte$ <br />p g ftikk SaWogolift inn or claim for payment <br />i <br />submitted to ESI by a Participating PharniW, Mail Service Pharmaey;uril $pW_Wty Pharmacy as a result <br />of dispensing Covered Drugs to a Member.: <br />12m.w iption Drue Program" means the specific pharmacy benefit management services and benefit design <br />sdopW by, and applicable to, Client under this Agreement. <br />"Primary Member" means each Member, excluding Members who are qualified dependents. <br />"Protected Health Information" or "PHI" shall have the meaning given such term y. 11M but l mi * <br />that information created or received by PBM. ' capacity ty $ s} Gontractot#*dminstritor dtit <br />Administrator in its Cap&* as a business assoO68*116 the Plan. <br />"Rebates' mean retrospective fort�r rebates that are paid to ESI pursuant to the terms of a formulary <br />rebase conttaot negotiated indjriy ESI with a pharmaceutical manufacturer and directly attributable <br />to the utiii2ation ofcertain CoveredHrugs by Members. Rebates do not include Manufacturer Administrative <br />Fees; product �t dloda*..or fear related to the procurement of prescription drug inventories, ESI Specialty <br />Pharmacy ,-fees received by ESI from pharmaceutical manufacturers for care <br />Pharma ala' � Mail Service P <br />managementor other services provided Ifivonnection with the dispensing ofproducts; or other flee-for-service <br />arrangementswhereby pharmaceutical manufacturers generally report the fees paid to ESI or its affiliates for <br />services rendered as "bola fide service fees"` <br />pursuant to federal laws and regulations (collectively, ' Other <br />Pbffi= Revenue"). Such laws and regulations, as well as ESIts< contracts with pharmaceutical <br />nuingfOott rers,.generally prohibit ESI from sharing any such "bona fide sawke fees" earned by ESI, whether <br />wh4y`or in part, with any ESI client. ESI represents and warrants that it W1 not enter into any ag pmt t <br />i %fts pharmaceutical manufacturer for Oth r Pharma Revenue with the i ttmtt tat to uce Rebaipt:: <br />Vtowangntt tON' lil�i 3" } IEIS tWREIN IS CONFIDE <br />Q TW. MTRAI NVC -T F ESI AND RXBENEFITS <br />79 <br />
The URL can be used to link to this page
Your browser does not support the video tag.